Literature DB >> 24503217

Chronic pruritus in HIV-positive patients in the southeastern United States: its prevalence and effect on quality of life.

Shivani B Kaushik1, Felipe B Cerci1, Jill Miracle2, Achyut Pokharel1, Suephy C Chen3, Yiong Huak Chan4, Aimee Wilkin2, Gil Yosipovitch5.   

Abstract

BACKGROUND: Prevalence of chronic pruritus in HIV-positive patients is an underevaluated topic in the United States. The characteristics, severity, and quality of life (QOL) in patients with HIV and chronic pruritus have not been well documented using validated tools.
OBJECTIVES: We sought to assess the prevalence and intensity of chronic pruritus and its effect on QOL in HIV-positive patients in a US population.
METHODS: HIV-positive patients (n = 201) were asked to complete a sociodemographic data form and 2 itch questionnaires. Patients with itching rated their itch intensity on a numeric visual analog scale. Laboratory parameters were obtained from patients' medical records.
RESULTS: The prevalence of chronic itch in the study group was 45% with an average visual analog scale score of 5.93 during an itch episode. Patients with high visual analog scale score had significantly decreased QOL. Patients with HIV reported greater negative impact of pruritus on daily lives. LIMITATIONS: Because of the cross-sectional design, this study demonstrates an association between HIV and pruritus but cannot prove causation.
CONCLUSION: Patients with HIV surveyed in a large clinic in the southeastern United States have a high prevalence of pruritus; HIV pruritus has a significant effect on QOL and itch is the most common skin manifestation found in this population.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  HIV; chronic pruritus; quality of life

Mesh:

Year:  2014        PMID: 24503217     DOI: 10.1016/j.jaad.2013.12.015

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  The skin and HIV: no superficial matter.

Authors:  Sareeta R S Parker
Journal:  Top Antivir Med       Date:  2014 Sep-Oct

2.  Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

Authors:  Saadet Inan; Alvaro Torres-Huerta; Liselotte E Jensen; Nae J Dun; Alan Cowan
Journal:  Eur J Pharmacol       Date:  2019-09-27       Impact factor: 4.432

3.  Cutaneous manifestations of human immunodeficiency virus: a clinical update.

Authors:  Kirstin Altman; Erin Vanness; Ryan P Westergaard
Journal:  Curr Infect Dis Rep       Date:  2015-03       Impact factor: 3.725

4.  Psychosocial Burden of Itch among Renal Transplant Recipients.

Authors:  Piotr K Krajewski; Kinga Tyczyńska; Klaudia Bardowska; Piotr Olczyk; Magdalena Krajewska; Jacek C Szepietowski
Journal:  Toxins (Basel)       Date:  2022-04-30       Impact factor: 5.075

Review 5.  Itch: Epidemiology, clinical presentation, and diagnostic workup.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Shawn G Kwatra
Journal:  J Am Acad Dermatol       Date:  2021-08-21       Impact factor: 11.527

Review 6.  Chronic pruritus in the elderly: pathophysiology, diagnosis and management.

Authors:  Rodrigo Valdes-Rodriguez; Carolyn Stull; Gil Yosipovitch
Journal:  Drugs Aging       Date:  2015-03       Impact factor: 4.271

7.  Cutaneous Manifestations of Human Immunodeficiency Virus/AIDS Patients in Albania.

Authors:  Erjona Shehu; Arjan Harxhi; Artan Simaku
Journal:  Int J Appl Basic Med Res       Date:  2019-10-11

Review 8.  Itch and Psyche: Bilateral Associations.

Authors:  Radomir Reszke; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

9.  Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.

Authors:  Saadet Inan; Nae J Dun; Alan Cowan
Journal:  Molecules       Date:  2021-09-11       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.